Drug Details
| General Information of the Drug (ID: DR5040) | ||||
|---|---|---|---|---|
| Name |
KML001
|
|||
| Disease | Lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Doxercalciferol | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
A combination of KML001 with doxercalciferol showed a synergistic effect on ALL cell lines. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor alpha (RARA) | Molecule Info | [3] | |
| Retinoic acid receptor beta (RARB) | Molecule Info | [3] | ||
| KEGG Pathway | Pathways in cancer | Click to Show/Hide | ||
| 2 | Small cell lung cancer | |||
| 3 | Non-small cell lung cancer | |||
| 4 | Transcriptional misregulation in cancer | |||
| 5 | Acute myeloid leukemia | |||
| Pathway Interaction Database | Retinoic acid receptors-mediated signaling | Click to Show/Hide | ||
| Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
| WikiPathways | Vitamin A and Carotenoid Metabolism | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Mesodermal Commitment Pathway | |||
| 4 | Integrated Pancreatic Cancer Pathway | |||
| 5 | Nuclear Receptors | |||
| 6 | Adipogenesis | |||
